IceCure Medical Ltd. (NASDAQ: ICCM) has entered into securities purchase agreements with healthcare-focused institutional investors for a $4 million registered direct offering and concurrent private placement, according to a company statement.

The Israeli medical device company will sell 8 million ordinary shares at $0.50 per share in the registered direct offering. The company expects gross proceeds of approximately $4 million before deducting placement agent fees and other expenses.

In a concurrent private placement, IceCure will issue Series B warrants to purchase up to 8 million ordinary shares and Series C warrants for an additional 8 million shares. Both warrant series carry an exercise price of $0.55 per share and are exercisable immediately upon issuance. The Series B warrants expire five years from issuance, while Series C warrants expire after one year.

The offering is expected to close on or about March 27, 2026, subject to customary closing conditions. IceCure plans to use net proceeds for working capital and general corporate purposes.

A.G.P./Alliance Global Partners serves as the sole placement agent for the offering. The ordinary shares are being offered under an effective shelf registration statement on Form F-3 that was declared effective by the SEC on March 24, 2026.

IceCure develops cryoablation technology systems that destroy tumors through freezing, focusing on breast, kidney, bone and lung cancer treatments. The company markets its ProSense system in the United States, Europe and Asia.